1xbet 철수., Ltd.

• Takeda has obtained New Drug Application approval in Japan 1xbet 철수 "VONOSAP^®1xbet 철수" and "VONOSAP^®1xbet 철수", each being a triple-drug blister pack containing the potassium-competitive acid blocker "TAKECAB^®tablet", developed by Takeda, 1xbet 철수 primary eradication ofHelicobacter pylori (H. pylori).
• Approval was also received 1xbet 철수 "VONOPION^®1xbet 철수", a triple-drug blister 1xbet 철수 containing "TAKECAB^®tablet" 1xbet 철수 secondary eradication ofH. pylori.
• As per the agreement reached at the end of March 2014 1xbet 철수 co-promotion of "TAKECAB^®tablet" in Japan, Takeda and Otsuka will implement in1xbet 철수mational activities on "VONOSAP^®1xbet 철수", "VONOSAP^®1xbet 철수" and "VONOPION^®1xbet 철수" for eradication ofH. pylori, thereby addressing the healthcare needs in acid-related disorders.
• Otsuka will be compensated 1xbet 철수 all sales generated by its sales 1xbet 철수ce 1xbet 철수 "TAKECAB^®tablet" as well 1xbet 철수 the TAKECAB^®-containing drug 1xbet 철수s, "VONOSAP^®1xbet 철수" and "VONOPION^®1xbet 철수".

Takeda Pharmaceutical Company Limited (Head office, Chuo-ku, Osaka; President and COO, Christophe Weber; hereafter "Takeda") and Otsuka Pharmaceutical Co., Ltd. (Head office, Chiyoda-ku, Tokyo; President and Representative Director, Tatsuo Higuchi; hereafter "Otsuka") announced that Takeda has obtained New Drug Application approval from the Ministry of Health, Labour and Welfare 1xbet 철수 "VONOSAP^®1xbet 철수", "VONOSAP^®1xbet 철수" (hereafter "VONOSAP") and "VONOPION^®1xbet 철수" (hereafter "VONOPION") forH. pylorieradication.
"VONOSAP" is a triple-drug blister 1xbet 철수 combining the acid suppressant (also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action) "TAKECAB^®tablet" (generic name, vonoprazan fumarate; hereafter "TAKECAB") developed by Takeda, "Amolin^®capsule" (generic name, amoxicillin; hereafter "Amolin") and "Clarith^®tablet" (generic name, clarithromycin) 1xbet 철수 primary eradication ofH. pyloriand "VONOPION" is a triple-drug blister 1xbet 철수 containing "TAKECAB", "Amolin" and "Fragile^®tablet" (generic name, metronidazole) 1xbet 철수 secondary eradication ofH. pylori.

Combining a daily dose of each of the two antibiotics used 1xbet 철수H. pylorieradication with TAKECAB, which is known to exert potent and sustained acid-inhibitory effects, these blister 1xbet 철수s have been developed to improve patient adherence by ensuring that each component drug is taken without fail. With the added benefit of convenience of use, these blister 1xbet 철수s are also expected to provide an alternative treatment option for healthcare professionals to effectively treat their patients. Otsuka and Takeda also hope to further contribute to improvingH. pylorieradication therapy in Japan.

• Helicobacter pyloriare one type of bacteria present in the human stomach and are primarily known to be implicated in the onset of peptic ulcer.H. pylorieradication therapy has been shown to be effective in preventing peptic ulcer recurrence with markedly low peptic ulcer recurrence rates reported following treatment, thus providing substantial benefits to patients withH. pyloriinfection.

Overview of VONOSAP

Overview of VONOPION